We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
+27.54%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
AUM
$435M
AUM Growth
+$56.3M
Cap. Flow
-$43.2M
Cap. Flow %
-9.92%
Top 10 Hldgs %
100%
Holding
4
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TXG icon
10x Genomics
TXG
+$43.2M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TXG icon
1
10x Genomics
TXG
$5.87B
$408M 93.76%
2,253,528
-250,000
-10% -$43.2M
NVAX icon
2
Novavax
NVAX
$1.23B
$12.2M 2.81%
67,373
EPZM
3
DELISTED
Epizyme, Inc
EPZM
$8.71M 2%
1,000,002
XLRN
4
DELISTED
Acceleron Pharma
XLRN
$6.22M 1.43%
45,884

Similar funds

Foresite Capital Management II's Q1 2021 Portfolio in Review

As of Q1 2021, Foresite Capital Management II held 4 positions worth $435M, up 15% from $379M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Foresite Capital Management II withdrew a net $43.2M in Q1 2021, reducing 1 holding. Its largest reduction was 10x Genomics, cutting an estimated $43.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management II's biggest Q1 2021 reduction was 10x Genomics, cutting an estimated $43.2M.
  • Foresite Capital Management II's ten largest holdings make up 100% of its $435M portfolio in Q1 2021.
  • Foresite Capital Management II opened 0 new positions and closed 0 in Q1 2021.
  • Foresite Capital Management II's portfolio value rose 15% quarter-over-quarter to $435M.

Based on Foresite Capital Management II's 13F filing for Q1 2021, filed 17 May 2021.